Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate - 17/08/15
Abstract |
Background |
Treatment of moderate to severe atopic dermatitis (AD) is often inadequate.
Objective |
We sought to evaluate the efficacy of the oral Janus kinase inhibitor tofacitinib citrate in the treatment of moderate to severe AD.
Methods |
Six consecutive patients with moderate to severe AD who had failed standard treatment were treated with tofacitinib citrate. Response to treatment was assessed using the Scoring of AD index.
Results |
Decreased body surface area involvement of dermatitis and decreased erythema, edema/papulation, lichenification, and excoriation were observed in all patients. The Scoring of AD index decreased by 66.6% from 36.5 to 12.2 (P < .05) during 8 to 29 weeks of treatment. There were no adverse events.
Limitations |
Small sample size, lack of placebo control group, and the possibility of bias are limitations.
Conclusion |
The oral Janus kinase inhibitor tofacitinib citrate may be beneficial in the treatment of moderate to severe AD.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, Janus kinase inhibitor, tofacitinib
Abbreviations used : AD, IL, JAK, QoL, SCORAD, STAT, Th2
Plan
Funding sources: None. |
|
Disclosure: Dr King has served on an advisory board for Pfizer. Drs Levy and Urban have no conflicts of interest to declare. |
Vol 73 - N° 3
P. 395-399 - septembre 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?